Details of the Drug

General Information of Drug (ID: DM9X2FV)

• Drug Name: Butyrfentanyl
• Synonyms: Butyr-fentanyl; Butyrfentanyl; Butyrfentanyl (Butyrylfentanyl); Butyryl fentanyl; Methyl-3-fentanyl; QQOMYEQLWQJRKK-UHFFFAOYSA-N; TRA0094848; ZINC32266443; 07V1H7R6ZN; 1169-70-6; AC1LDM56; AKOS025243418; AS-48590; Butanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-; CS-D0505; CTK0G0348; DB09173; DEA No. 9822; DTXSID30347410; MFCD22054430; N-(1-Phenethylpiperidin-4-yl)-N-phenylbutyramide; N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]BUTANAMIDE; N-Phenyl-N-(1-phenethyl-4-piperidinyl)butanamide; SCHEMBL18623773; UNII-07V1H7R6ZN

Indication

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Investigative	[1]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 350.5
  Topological Polar Surface Area (xlogp); 4.4
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property: Metabolism: The drug is metabolized via the hydroxylation of CYP3A4 and CYP2D6 [2]
• Chemical Identifiers:
  Formula: C23H30N2O
  IUPAC Name: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide
  Canonical SMILES: CCCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
  InChI: QQOMYEQLWQJRKK-UHFFFAOYSA-N
  InChIKey: 1S/C23H30N2O/c1-2-9-23(26)25(21-12-7-4-8-13-21)22-15-18-24(19-16-22)17-14-20-10-5-3-6-11-20/h3-8,10-13,22H,2,9,14-19H2,1H3
• Cross-matching ID:
  PubChem CID: 621174
  CAS Number: 1169-70-6
  DrugBank ID: DB09173
  INTEDE ID: DR0250

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[4]

References

• [1] Butyrfentanyl (Butyrylfentanyl) Critical Review Report.
• [2] Bezchlibnyk-Butler K, Aleksic I, Kennedy SH: Citalopram--a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000 May;25(3):241-54.
• [3] Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol Pharm Bull. 2019;42(4):623-630.
• [4] Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). Drug Test Anal. 2017 Jul;9(7):1085-1092.
• [5] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [6] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [7] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [8] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [9] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [10] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [11] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [12] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [13] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [14] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [15] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [16] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [17] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [18] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [19] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [20] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [21] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.